6533b85dfe1ef96bd12bdfcc
RESEARCH PRODUCT
Cyclophosphamide plus Epidoxorubicin and 5-Fluorouracil with Folinic Acid as a Novel Treatment in Metastatic Breast Cancer: Preliminary Results of a Phase II Study
Sergio PalmeriNicolo' GebbiaMaria MeliAntonio RussoVittorio GebbiaLuciano Rausasubject
Adult0301 basic medicinemedicine.medical_specialtyCyclophosphamide030106 microbiologyLeucovorinPhases of clinical researchBreast NeoplasmsGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideEpirubicinPharmacologyLeukopeniabusiness.industryRemission InductionCancerMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisDrug EvaluationFemaleFluorouracilmedicine.symptombusinessmedicine.drugdescription
Twenty consecutive patients with advanced breast cancer were treated with a combination of cyclophosphamide 600 mg/m2 i.v. on day 1, epidoxorubicin 75 mg/m2 on day 1, and 5-fluorouracil 375 mg/m2 i.v. with folinic acid 200 mg/m2 i.v. on days 1----3. The overall response rate was 60%, with 10% of patients showing a complete response with a mean duration of 11.1 + months, and 50% of patients a partial response of 7.4 + months. A stabilization of 5.2 + months was obtained in 20% of cases, while 20% of patients progressed. The most frequently observed toxicity was leukopenia, while expected mucosal toxicities were rather mild.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1991-06-01 | Journal of Chemotherapy |